KPV Peptide: Uses, Dosage, Benefits & 2026 FDA Status
KPV is a three-amino-acid peptide (lysine-proline-valine) cut from the tail end of alpha-MSH, a hormone the body uses to regulate inflammation. That tiny fragment keeps most of the anti-inflammatory punch of the full hormone while being more stable, which is why it shows up in research on gut disease, skin conditions, and systemic inflammation. This page is the plain-English hub: what KPV is, how it works, how it is dosed, its safety profile, and where it stands in the July 2026 FDA compounding review.
What Is KPV Peptide?
KPV is a tripeptide: lysine, proline, and valine linked in sequence. It is the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), a melanocortin peptide that controls pigmentation, appetite, and, relevant here, inflammation. When researchers stripped alpha-MSH down to its shortest active piece, they found that the KPV sequence retained the anti-inflammatory activity without the pigmentation effects of the full hormone.
Because it is so short, KPV is more chemically stable and cheaper to synthesize than larger peptides. It is studied as both an injectable and an oral compound. If you are new to peptides generally, start with our overview of what peptides are and how fragments like this differ from full-length hormones.
KPV and the July 2026 FDA Compounding Review
KPV is one of seven peptides the FDA Pharmacy Compounding Advisory Committee (PCAC) took up at its July 23-24, 2026 meeting. Day one covered KPV, BPC-157, TB-500, and MOTS-c. The nomination lists KPV for wound healing and inflammatory conditions.
Ahead of the meeting, FDA career scientists posted briefing materials recommending against adding any of the seven peptides to the 503A bulks list, citing insufficient safety and effectiveness evidence. The committee overrode them. KPV was recommended 8-6 with one abstention, matching BPC-157 and TB-500; MOTS-c cleared 7-5. On Day 2 Semax passed 8-5 and Epitalon 7-5, and emideltide (DSIP) was rejected 6-7, the only no of the two days. A committee recommendation is not a binding decision. The FDA issues any final rule separately through formal rulemaking that takes months to more than a year, and it is free to side with its own reviewers.
Practically, nothing changed on July 23. KPV is still not a peptide that traditional compounding pharmacies can legally make from bulk powder, and a favorable committee vote did not put it on the list. If a vendor tells you the PCAC vote made KPV legal, that is wrong. For the vote detail, the evidence reviewed, and the rulemaking timeline ahead, see our PCAC hearing guide and the broader picture of peptide legality.
How KPV Works
KPV's main mechanism is inhibition of NF-kB, a signaling protein that switches on genes for pro-inflammatory cytokines like TNF-alpha, IL-6, and IL-8. By interrupting that pathway inside the cell, KPV lowers the production of those cytokines at the source rather than mopping them up afterward.
It also signals through melanocortin receptors (MC1R and MC3R) on immune cells, which raises anti-inflammatory mediators like IL-10 and nudges immune balance toward tolerance. Some research points to direct antimicrobial activity as well. The combination of calming inflammation while preserving normal immune defense is what makes KPV interesting compared with blunt immunosuppressants.
Researched Benefits
The strongest evidence is for gut inflammation. In inflammatory bowel disease models, KPV reduces inflammatory markers and helps restore the tight junctions that keep the intestinal barrier intact. That gut focus is why it is often paired with repair peptides. Our KPV for gut health guide goes deeper on the intestinal data.
Beyond the gut, KPV is studied for skin conditions (acne, eczema, psoriasis) through combined anti-inflammatory and antimicrobial action, and for general systemic inflammation. For the full breakdown of each application and the evidence level behind it, see our dedicated KPV benefits guide.
Dosage Overview
There is no FDA-approved dose for KPV because it is not an approved drug. Reported research protocols for subcutaneous use commonly sit around 200 to 500 mcg per day. Oral doses run higher to compensate for lower absorption. Timing, cycle length, and whether it is stacked with other peptides all vary by goal.
Reconstitution matters for the injectable form: lyophilized KPV powder is mixed with bacteriostatic water before dosing. If you are working out concentrations, our reconstitution guide and the full KPV dosage guide cover the math and the reported ranges.
Forms: Injectable, Oral, and Topical
KPV appears in three main formats. Subcutaneous injection gives the most direct systemic exposure and uses the lowest doses. Oral capsules are convenient and favored for gut-local goals, though systemic absorption is lower; our KPV capsules guide covers that route. Topical KPV is used in some skin formulations.
Storage affects potency across all forms. Reconstituted peptide is refrigerated and has a limited shelf life; lyophilized powder keeps longer. See our peptide storage guide and, for injection technique, how to inject peptides.
KPV vs BPC-157, TB-500, and Other Peptides
KPV is an anti-inflammatory; BPC-157 and TB-500 are repair and recovery peptides. That is why KPV is more often combined with them than compared head-to-head: KPV calms the inflammatory environment while the others support tissue rebuilding. Our BPC-157 vs TB-500 comparison explains how the two repair peptides differ.
KPV shares the July 2026 PCAC spotlight with those peptides plus MOTS-c, and the second day of the hearing covered DSIP (emideltide), Semax, and Epitalon. For combining peptides safely, see our peptide stacks guide.
Safety and Side Effects
In the available research, KPV is well tolerated. Reported side effects are mild: injection-site reactions, occasional nausea, and headache. Unlike broad immunosuppressants, it does not appear to raise infection risk, which is one reason researchers find the selective mechanism appealing.
The real-world risks are less about the molecule and more about the market: research-grade KPV varies in purity, dose accuracy, and sterility. Long-term human safety data are limited. Our KPV side effects guide covers what is documented and what is still unknown.
Sourcing and Quality
Because KPV is not on the 503A bulks list, compounding pharmacies generally cannot dispense it to patients right now, so most supply is research-grade material labeled for laboratory use. That places the quality burden on the buyer. Third-party purity testing (HPLC), certificates of analysis, and sterility are the things that separate reputable suppliers from the rest.
Our guide on where to buy peptides and the overview of compounding pharmacy peptides explain how to read a certificate of analysis and what changes if the PCAC review eventually opens a compounding pathway.
Bottom Line
KPV is a small, stable anti-inflammatory peptide with a coherent mechanism and the most support for gut inflammation, with secondary interest in skin and systemic inflammation. It is not FDA-approved, human data are still limited, and its legal status hinges partly on the July 2026 PCAC review. If you are researching it, treat dosing figures as estimates, prioritize tested material, and involve a licensed clinician. From here, the natural next steps are the benefits, dosage, and gut health guides.
Frequently Asked Questions About KPV
KPV is a tripeptide made of three amino acids: lysine (K), proline (P), and valine (V). It is the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). Researchers study it because that short sequence keeps most of the parent hormone's anti-inflammatory activity while being smaller and more stable. It is used in research and compounding settings for inflammation, gut conditions, and skin, not as an FDA-approved drug.
KPV is not an FDA-approved drug, and it is still not on the 503A bulks list that lets compounding pharmacies make it from bulk powder. On July 23, 2026 the FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8-6, with one abstention, to recommend adding KPV to that list, along with BPC-157 and TB-500 at the same margin and MOTS-c at 7-5. That went against FDA career scientists, who had recommended against all seven peptides on insufficient-evidence grounds. The vote is advisory and the FDA has not issued a final rule, so nothing about KPV changed legally on July 23. Until rulemaking finishes, KPV mostly circulates as research-grade material. See our PCAC hearing guide for the current status.
Reported research protocols commonly fall in the 200 to 500 mcg per day range for subcutaneous use, and higher for oral capsules because oral bioavailability is lower. There is no FDA-approved dose because KPV is not an approved drug, and human dosing data are limited. Anyone considering it should work with a licensed clinician. Our KPV dosage guide breaks down the reported ranges by goal and route.
Injectable (subcutaneous) KPV bypasses the digestive tract and reaches circulation directly, which is why injected doses are lower. Oral KPV capsules are convenient and are often chosen for gut-specific goals because the peptide acts locally in the intestine, but systemic absorption is lower and less predictable. The best route depends on whether the target is local gut inflammation or a systemic effect. See our KPV capsules guide for the oral option.
They work by different mechanisms and are often studied together rather than as rivals. KPV is an anti-inflammatory that dampens NF-kB signaling and calms immune activity. BPC-157 is a repair-oriented peptide that supports angiogenesis and tissue healing. For inflammatory gut conditions, some practitioners combine them. Neither is FDA-approved for these uses. Compare the two directly in our BPC-157 gut healing guide.
Reported side effects are generally mild and include injection-site reactions, occasional nausea, and headache. KPV does not appear to broadly suppress the immune system the way conventional immunosuppressants do, which is part of its research appeal. Long-term human safety data are thin, and product purity varies widely in the research-grade market. Our KPV side effects guide covers what is known and what remains uncertain.
This varies by condition and is not well established in controlled human trials. Anecdotal reports and small studies for gut and skin inflammation describe changes over two to six weeks of consistent use. Because the evidence base is mostly preclinical and early clinical, timelines should be treated as rough estimates rather than guarantees.
Most KPV on the market is sold as research-grade material labeled for laboratory use only, not for human consumption. Because it is not on the 503A bulks list, compounding pharmacies generally cannot make it for patients right now. Purity, dose accuracy, and sterility are the main risks with research-grade sources. Our guide on where to buy peptides explains how to evaluate vendors and third-party testing.